Q-omics provides the consensus-scored KLC1 profile across patient tissues and cancer cell-line models. KLC1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KLC1 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, KLC1 RNA expression shows 19,806 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where KLC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLC1 survival associations across molecular data types. KLC1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLC1 RNA expression–survival associations across cancer types. High KLC1 expression shows unfavorable associations in ACC, KIRC, UVM, PRAD and COAD, but favorable associations in THYM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KLC1 RNA expression.
This table summarizes KLC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KLC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLC1 shows lower tumor expression in BRCA and LUAD and higher tumor expression in HNSC, LIHC, COAD and CHOL. The HNSC box plot shows higher KLC1 RNA expression in tumor versus normal tissue (log2 FC = +0.515, t-test p < 0.001).
This table shows molecular features associated with KLC1 in patient tissues and cancer cell lines. In patient samples, KLC1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
